Zoetis (ZTS) to Release Earnings on Thursday
Zoetis (NYSE:ZTS) will announce its earnings results before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of $0.66 per share for the quarter.
Shares of Zoetis (NYSE:ZTS) opened at $73.24 on Wednesday. The company has a market capitalization of $35,690.00, a price-to-earnings ratio of 38.55, a P/E/G ratio of 1.60 and a beta of 1.07. Zoetis has a 12 month low of $52.00 and a 12 month high of $80.13. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.69%. The ex-dividend date is Thursday, January 18th. This is an increase from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is presently 26.32%.
COPYRIGHT VIOLATION WARNING: “Zoetis (ZTS) to Release Earnings on Thursday” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/zoetis-zts-to-release-earnings-on-thursday.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.